Should I Buy EDIT? EDIT 2026 Analysis

Should You Buy Editas Medicine Inc (EDIT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.820

1 Day change

9.31%

52 Week Range

4.540

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price action and trend signals remain bearish and the near-term pattern model implies further downside over 1 week to 1 month.
Best approach is to avoid new long entries until price reclaims key resistance (~2.15 pivot) with improving momentum; current setup favors downside continuation or choppy bounces.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend is bearish: moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), implying sustained downtrend.
Momentum is weakening: MACD histogram is below zero and negatively expanding (bearish continuation).
RSI(6) ~36.7: approaching oversold but not a clean reversal signal; can stay weak in a downtrend.
Key levels: Support S1 ~1.95 (very close to current 1.98) then S2 ~1.83; Resistance pivot ~2.145 then R1 ~2.34.
Short-term pattern stats (similar candlesticks): ~70% chance of -0.98% next day, -2.5% next week, -11.83% next month—skewed bearish near-term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment is mixed-to-bearish near-term: open interest put/call is low (0.2, call-heavy positioning), but today’s volume put/call is very high (3.14), signaling fresh bearish demand/hedging.
Put volume (232) dominates call volume (74) today, reinforcing short-term defensive/bearish flow.
Implied volatility is elevated (30D IV ~~104%) vs historical volatility (~~67.8%), suggesting the market is pricing large moves; IV percentile ~38 / IV rank ~25 implies not peak-panic, but still expensive options.
Volume is light vs recent averages (today 306 vs 5D avg 610; 10D avg 850), so the bearish skew is notable but not backed by heavy overall participation.

Technical Summary

Sell

Buy

Positive Catalysts

- Hedge funds are reported as net buyers (buying amount up ~500% QoQ), which can provide support at depressed prices.
- Analysts maintaining Buy ratings (per provided notes) suggest Street still sees upside optionality tied to pipeline progress (e.g., EDIT-401 timeline reiterated).
- Price is sitting just above nearby support (~1.95); oversold-ish RSI can allow short, tactical dead-cat bounces.

Neutral/Negative Catalysts

- No near-term news catalysts in the last week; without a trigger, the prevailing downtrend can continue.
- Technicals are decisively bearish (MA stack + negative MACD expansion), increasing odds of support breaks (1.95 then 1.83).
- Options tape shows bearish flow today (put volume dominance), consistent with traders positioning for downside.
- Pattern-based forward view points to continued weakness over 1 week to 1 month.
- No notable insider buying trend recently (insiders neutral), reducing confidence in an imminent fundamental floor.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue rose to $7.54M (+12265.57% YoY), likely driven by non-recurring/partnering dynamics rather than steady commercial scale (given overall loss profile).
Profitability remains weak: Net income - $25.12M (still a sizable loss) and EPS -0.28 (worse YoY by -62.67%).
Gross margin reported at 100% (often reflects accounting/low cost-of-revenue dynamics at this stage, not necessarily sustainable operating leverage).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent Street actions (provided):
- 2025-11-12 Chardan: PT cut to $3.50 from $12, kept Buy (big reset lower despite bullish rating).
- 2025-11-10 Clear Street: PT raised to $4.60 from $4, kept Buy (post-Q3, timeline maintained).
Trend summary: Ratings remain Buy, but targets are relatively low and volatile—signals high uncertainty and risk-adjusted optimism rather than strong conviction.
Wall Street pros: sees upside optionality from gene-editing pipeline execution (EDIT-401) and depressed price as an opportunity.
Wall Street cons: significant target cuts and low probability-of-success framing highlight binary biotech risk and execution uncertainty.

10 Analyst Rating

Wall Street analysts forecast EDIT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDIT is 4.02 USD with a low forecast of 3 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

5 Hold

1 Sell

Moderate Buy

Current: 1.665

Low

Averages

4.02

High

Current: 1.665

Low

Averages

4.02

High

Chardan

Buy

downgrade

$12

AI Analysis

2025-11-12

Reason

Chardan

Price Target

$12

AI Analysis

2025-11-12

downgrade

Buy

Reason

Chardan lowered the firm's price target on Editas Medicine to $3.50 from $12 and keeps a Buy rating on the shares. The firm updated its Editas model for Q3 results and progress on lead in vivo gen editing candidate EDIT-401. The firm noted the space's pullback has created a buying opportunity.

Clear Street

Buy

maintain

2025-11-10

Reason

Clear Street

Price Target

2025-11-10

maintain

Buy

Reason

Clear Street raised the firm's price target on Editas Medicine to $4.60 from $4 and keeps a Buy rating on the shares following the Q3 report. The company maintained previously stated timelines for EDIT-401, the analyst tells investors in a research note. The firm sees $1.8B in peak sales and a 10% likelihood of success.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EDIT

Unlock Now

EDIT Should I Buy

EDIT Should I Buy

Should You Buy Editas Medicine Inc (EDIT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch